Establishment of a transgenic mouse model specifically expressing human serum amyloid a in adipose tissue

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Olsson, Maja ^a   Ahlin, Sofie ^a   Olsson, Bob ^a   Svensson, Per Arne ^a   Ståhlman, Marcus ^a   Borén, Jan ^a   Carlsson, Lena M S ^a   Sjöholm, Kajsa ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; SERUM AMYLOID A; BIOLOGICAL MARKER; LIPOPROTEIN; MESSENGER RNA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; FAST PROTEIN LIQUID CHROMATOGRAPHY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SERUM AMYLOID A GENE; TISSUE SPECIFICITY; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANIMAL MODEL; BLOOD; BODY COMPOSITION; BODY WEIGHT; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NONPARAMETRIC TEST;

ANIMALIA; MUS MUSCULUS;

ADIPOSE TISSUE; ANIMALS; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY WEIGHT; CHOLESTEROL; GENE EXPRESSION REGULATION; HUMANS; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, ANIMAL; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; STATISTICS, NONPARAMETRIC;

EID: 79956226871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019609     Document Type: Article

References (49)

1. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, (1999) Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults. N Eng J Med 341: 1097-1105.
2. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, et al. (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3: e287.
3. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW, (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972-978.
4. Kosuge M, Ebina T, Ishikawa T, Hibi K, Tsukahara K, et al. (2007) Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J 71: 186-190.
5. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, et al. (2004) Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109: 726-732.
6. Jylhävä J, Haarala A, Eklund C, Pertovaara M, Kahonen M, et al. (2009) Serum amyloid A is independently associated with metabolic risk factors but not with early atherosclerosis: the Cardiovascular Risk in Young Finns Study. J Intern Med 266: 286-295.
7. Sjöholm K, Lundgren M, Olsson M, Eriksson JW, (2009) Association of serum amyloid A levels with adipocyte size and serum levels of adipokines: differences between men and women. Cytokine 48: 260-266.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N, (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843.
9. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y, (1998) Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 46: 1377-1384.
10. Sjöholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, et al. (2005) A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 90: 2233-2239.
11. Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, et al. (2005) Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 48: 519-528.
12. Jernås M, Palming J, Sjöholm K, Jennische E, Svensson PA, et al. (2006) Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J 20: 1540-1542.
13. Salans LB, Knittle JL, Hirsch J, (1968) The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. J Clin Invest 47: 153-165.
14. Wang YC, Kuo WH, Chen CY, Lin HY, Wu HT, et al. (2009) Docosahexaenoic acid regulates serum amyloid A protein to promote lipolysis through down regulation of perilipin. J Nutr Biochem.
15. Su SB, Gong W, Gao JL, Shen W, Murphy PM, et al. (1999) A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 189: 395-402.
16. Hatanaka E, Monteagudo PT, Marrocos MS, Campa A, (2007) Interaction between serum amyloid A and leukocytes- a possible role in the progression of vascular complications in diabetes. Immunol Lett 108: 160-166.
17. van der Westhuyzen DR, de Beer FC, Webb NR, (2007) HDL cholesterol transport during inflammation. Curr Opin Lipidol 18: 147-151.
18. Poitou C, Divoux A, Faty A, Tordjman J, Hugol D, et al. (2009) Role of serum amyloid a in adipocyte-macrophage cross talk and adipocyte cholesterol efflux. J Clin Endocrinol Metab 94: 1810-1817.
19. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, et al. (1986) Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 261: 9644-9651.
20. Ancsin JB, Kisilevsky R, (1999) The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 274: 7172-7181.
21. Lewis KE, Kirk EA, McDonald TO, Wang S, Wight TN, et al. (2004) Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 110: 540-545.
22. O'Brien KD, McDonald TO, Kunjathoor V, Eng K, Knopp EA, et al. (2005) Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 25: 785-790.
23. Wilson PG, Thompson JC, Webb NR, de Beer FC, King VL, et al. (2008) Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 173: 1902-1910.
24. Scheja L, Heese B, Zitzer H, Michael MD, Siesky AM, et al. (2008) Acute-phase serum amyloid A as a marker of insulin resistance in mice. Exp Diabetes Res 2008: 230837.
25. Chiba T, Han CY, Vaisar T, Shimokado K, Kargi A, et al. (2009) Serum amyloid A3 does not contribute to circulating SAA levels. J Lipid Res 50: 1353-1362.
26. Uhlar CM, Whitehead AS, (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265: 501-523.
27. Hosoai H, Webb NR, Glick JM, Tietge UJ, Purdom MS, et al. (1999) Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res 40: 648-653.
28. Kindy MS, de Beer MC, Yu J, de Beer FC, (2000) Expression of mouse acute-phase (SAA1.1) and constitutive (SAA4) serum amyloid A isotypes: influence on lipoprotein profiles. Arterioscler Thromb Vasc Biol 20: 1543-1550.
29. Cabana VG, Feng N, Reardon CA, Lukens J, Webb NR, et al. (2004) Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res 45: 317-325.
30. Ross SR, Graves RA, Greenstein A, Platt KA, Shyu HL, et al. (1990) A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo. Proc Natl Acad Sci U S A 87: 9590-9594.
31. Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, et al. (1995) Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 95: 2246-2257.
32. Ståhlman M, Davidsson P, Kanmert I, Rosengren B, Borén J, et al. (2008) Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res 49: 481-490.
33. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, et al. (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602-26614.
34. Longo KA, Wright WS, Kang S, Gerin I, Chiang SH, et al. (2004) Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem 279: 35503-35509.
35. Poitou C, Coussieu C, Rouault C, Coupaye M, Cancello R, et al. (2006) Serum amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic status. Obesity (Silver Spring) 14: 309-318.
36. Han CY, Subramanian S, Chan CK, Omer M, Chiba T, et al. (2007) Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes 56: 2260-2273.
37. Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, et al. (2000) The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 97: 11371-11376.
38. Soukas A, Cohen P, Socci ND, Friedman JM, (2000) Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev 14: 963-980.
39. Kim SJ, Jung JY, Kim HW, Park T, (2008) Anti-obesity effects of Juniperus chinensis extract are associated with increased AMP-activated protein kinase expression and phosphorylation in the visceral adipose tissue of rats. Biol Pharm Bull 31: 1415-1421.
40. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, et al. (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7: 699-705.
41. Annema W, Nijstad N, Tolle M, de Boer JF, Buijs RV, et al. (2010) Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response, but not group IIA secretory phospholipase A2. J Lipid Res.
42. Benditt EP, Eriksen N, (1977) Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A 74: 4025-4028.
43. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, et al. (2003) Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res 44: 780-792.
44. de Beer MC, Webb NR, Wroblewski JM, Noffsinger VP, Rateri DL, et al. (2010) Impact of serum amyloid A on high density lipoprotein composition and levels. J Lipid Res.
45. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, et al. (2008) Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis 196: 248-255.
46. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, et al. (2009) Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302: 37-48.
47. Buyukhatipoglu H, Tiryaki O, Tahta K, Usalan C, (2007) Inflammation as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis in haemodialysis patients: the role of chlamydia and cytomegalovirus infection. Nephrology (Carlton) 12: 25-32.
48. Uurtuya S, Kotani K, Koibuchi H, Taniguchi N, Yamada T, (2009) Serum amyloid A protein and carotid intima-media thickness in healthy young subjects. J Atheroscler Thromb 16: 299-300.
49. King VL, Hatch NW, Chan HW, de Beer MC, de Beer FC, et al. (2010) A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring) 18: 35-41.